William T. Curry

Active 2005–2025

92
Papers
24,248
Citations
61
h-index
85
i10-index

Citations

Citations per year for William T. Curry1991: 1 citations1993: 1 citations1998: 2 citations2003: 2 citations2005: 2 citations2006: 3 citations2007: 13 citations2008: 25 citations2009: 49 citations2010: 96 citations2011: 117 citations2012: 186 citations2013: 189 citations2014: 248 citations2015: 276 citations2016: 309 citations2017: 406 citations2018: 387 citations2019: 1,037 citations2020: 1,435 citations2021: 1,407 citations2022: 1,130 citations2023: 859 citations2024: 1,415 citations2025: 791 citations2026: 27 citations1992: no citations, so this year is not shown1994–1997: no citations, so these years are not shown1999–2002: no citations, so these years are not shown2004: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,236 citing papers, 29.7% of this breakdownChina: 2,025 citing papers, 14.2% of this breakdownGermany: 845 citing papers, 5.9% of this breakdownUnited Kingdom: 679 citing papers, 4.8% of this breakdownItaly: 620 citing papers, 4.4% of this breakdownCanada: 439 citing papers, 3.1% of this breakdownFrance: 411 citing papers, 2.9% of this breakdownNetherlands: 353 citing papers, 2.5% of this breakdownAustralia: 344 citing papers, 2.4% of this breakdownJapan: 343 citing papers, 2.4% of this breakdownSpain: 330 citing papers, 2.3% of this breakdownSwitzerland: 295 citing papers, 2.1% of this breakdown
0%29.7%Other 23.3%

Fields

  • Biochemistry, Genetics and Molecular Biology47.4%
  • Medicine42.1%
  • Immunology and Microbiology4.5%
  • Neuroscience2.8%
  • Engineering1.2%
  • Materials Science0.4%
  • Other1.6%

Topics

  • Extracellular vesicles in disease9.1%
  • Glioma Diagnosis and Treatment8.7%
  • MicroRNA in disease regulation7%
  • Single-cell and spatial transcriptomics3%
  • Cancer Genomics and Diagnostics2.9%
  • CAR-T cell therapy research2.7%
  • Other66.6%

Coauthors

All papers

Open in search
  1. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christine Haberler, René Geyeregger, Thomas Czech, Irene Slavc, Brian V. Nahed, William T. Curry, Bob S. Carter, Hiroaki Wakimoto, Priscilla K. Brastianos, Tracy T. Batchelor, Anat Stemmer‐Rachamimov, Maria Martinez‐Lage, Matthew P. Frosch, Ivan Stamenkovic, Nicolò Riggi, Esther Rheinbay, Michelle Monje, Orit Rozenblatt–Rosen, Daniel P. Cahill, Anoop P. Patel, Tony Hunter, Inder M. Verma, Keith L. Ligon, David N. Louis, Aviv Regev, B Bernstein, Itay Tirosh, Mario L. Suvà - Cell 2019 cited by 2,988

  2. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers

    Authors: , , , , , , , , - Nature Cell Biology 2008 cited by 4,997

  3. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma

    Authors: , , , , , , , , , , - New England Journal of Medicine 2024 cited by 402

  4. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gad Getz, Orit Rozenblatt–Rosen, Daniel P. Cahill, Michelle Monje, B Bernstein, David N. Louis, Aviv Regev, Mario L. Suvà - Nature 2016 cited by 1,372

  5. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David N. Louis, B Bernstein, Aviv Regev, Mario L. Suvà - Science 2017 cited by 1,090

  6. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

    Authors: , , , , , , , , , , , , , , , , , , - Nature Biotechnology 2019 cited by 558

  7. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2018 cited by 664

  8. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael S. Rabin, Nancy U. Lin, Eric P. Winer, Anat Stemmer‐Rachamimov, Matthew Meyerson, Levi A. Garraway, Stacey Gabriel, Eric S. Lander, Rameen Beroukhim, Tracy T. Batchelor, José Baselga, David N. Louis, Gad Getz, William C. Hahn - Cancer Discovery 2015 cited by 1,136

  9. Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Cell 2014 cited by 973

  10. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 159

  11. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

    Authors: , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2019 cited by 283

  12. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

    Authors: , , , , , , , , , , , , , , - Science 2014 cited by 330

  13. A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2019 cited by 272

  14. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2015 cited by 445

  15. Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , - Neuro-Oncology Advances 2022 cited by 74

  16. BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 135

  17. Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment

    Authors: , , , , , , , , , , , - Clinical Cancer Research 2007 cited by 441

  18. Human Glioblastoma–Derived Cancer Stem Cells: Establishment of Invasive Glioma Models and Treatment with Oncolytic Herpes Simplex Virus Vectors

    Authors: , , , , , , , , , , , , , , - Cancer Research 2009 cited by 359

  19. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Neuro-Oncology 2017 cited by 202

  20. TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas

    Authors: , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 cited by 82

  21. Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression

    Authors: , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2014 cited by 250

  22. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2022 cited by 112

  23. NCCN Guidelines Insights: Bone Cancer, Version 2.2017

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jillian L. Scavone - Journal of the National Comprehensive Cancer Network 2017 cited by 299

  24. Immunohistochemical characterization of human olfactory tissue

    Authors: , , , , - The Laryngoscope 2011 cited by 183